We covered the HIV surge earlier in this series. But antiviral chemistry is moving well beyond it. A separate cluster is accelerating across hepatitis C and B, influenza, and coronaviruses — four virus families that share little except a growing crowd of chemists working on them. Read together, the pattern is unusually disciplined: the new chemistry is not scattered across dozens of exotic targets. It keeps returning to the same two places.
From the Knitify Pharma Demand Radar — our running read on where pharmaceutical demand is heading. We publish the observations; the method behind them stays in-house.
Nearly all of it hits one of two enzymes
Across those four virus families, the accelerating chemistry keeps landing on the same two targets: the viral protease — the molecular scissors a virus uses to cut its proteins into working parts — and the viral polymerase — the copier it uses to replicate its genome. Block either machine and the virus stalls. That is the whole logic in one sentence, and it explains why a signal spread over hepatitis, influenza, and coronaviruses can still look like a single strategy.
The protease matters because many of these viruses translate their genome as one long, continuous string of proteins — a polyprotein that is inert until it is snipped into individual working pieces. The virus carries its own scissors to make those precise cuts. Jam the scissors and the string never matures: no functional machinery gets assembled, and replication grinds to a halt. Coronaviruses do this with a main protease (often written as Mpro or 3CL); hepatitis C uses its own protease, NS3, to the same end. Different viruses, structurally similar problem, structurally similar solution.
The polymerase is the other choke point. To spread, a virus has to copy its genome, and RNA viruses carry an RNA-dependent polymerase — an RdRp — to do it. That enzyme has no real human counterpart, which is exactly what makes it a clean target: a drug that blocks it has little to hit in our own cells. The classic tactic is a nucleotide mimic, a decoy building block the copier grabs by mistake, after which the growing chain stalls or corrupts. Hepatitis B reaches replication through a reverse transcriptase rather than a conventional polymerase, but the same decoy logic applies. And because both the scissors and the copier do jobs too central to drift very far, their business ends are conserved — stable enough that a molecule designed against one virus has a genuine shot at a relative.
Hepatitis C is the proof the playbook pays
None of this is theoretical. Hepatitis C is the case study that turned direct-acting antiviral chemistry from an elegant hypothesis into an industry template. For years the disease was treated with an older regimen of interferon injections and ribavirin — long, poorly tolerated, and far from a reliable cure. It was the kind of treatment patients endured rather than welcomed.
Then came direct-acting antivirals: molecules aimed straight at proteins the virus cannot do without — a polymerase inhibitor at the core, combined with agents against other essential viral targets (an NS5A replication protein, and in some regimens a protease inhibitor) — usually packaged together in a single daily pill. Combining mechanisms was not a marketing flourish; hitting several conserved targets at once makes it far harder for the virus to mutate its way out of trouble. The result was a chronic, liver-destroying infection converted into a curable one in a matter of weeks, for the great majority of patients. That outcome is the reason "attack the conserved enzymes, and combine them" is now the reflex the accelerating chemistry against the next threats is reaching for.
Narrow drugs versus broad-spectrum bets
To see why that reflex matters commercially, it helps to separate two kinds of antiviral. A narrow drug is exquisitely tuned to one virus — often superbly effective, but brittle. The moment a new pathogen arrives from a neighboring family, a narrow drug is frequently useless, and the years of work behind it start again from scratch. That is the old "one bug, one drug" world, and it is a poor fit for a threat landscape where the dangerous virus is usually the one nobody was working on yet.
A broad-spectrum antiviral makes the opposite trade. By aiming at a feature many viruses share — a conserved protease pocket, or a polymerase gullible enough to swallow the same decoy nucleotide — it gives up some perfect-fit potency in exchange for reach across a family, or several. The protease-and-polymerase strategy is attractive precisely because it is mechanism-general: the same chemical idea ports from one virus to the next. That portability is the quiet thesis running underneath the whole signal. Suppliers are not betting on hepatitis, or influenza, or the next coronavirus specifically. They are building chemistry that would still be relevant whichever of those turns hot.
Readiness is now a funded mandate
After 2020, "have broad antiviral chemistry on the shelf" stopped being an academic exercise and became government policy. Preparedness agencies — BARDA in the United States, HERA in Europe — now explicitly back broad-spectrum antivirals with novel mechanisms, and the funding models under discussion tie payment to stockpiled doses and to maintained, ready-to-scale manufacturing capacity. [2] The template everyone points to is the COVID antiviral Paxlovid, whose active molecule inhibits the coronavirus main protease — a working demonstration that a protease inhibitor could be stood up fast against a new family. [1]
What makes this demand unusual is its shape. An ordinary drug market pays per unit sold during an outbreak, which means the best public-health outcome — no outbreak — is also the worst revenue outcome, and no rational company stocks for a crisis that may never come. Governments fix that inversion with "pull" mechanisms: advance purchase commitments, guaranteed procurement into national stockpiles, and money to keep "warm-base" manufacturing lines standing and ready to surge. The payment is attached to readiness — doses on the shelf, capacity that can run on short notice — rather than to units moved in a panic.
That is a fundamentally different demand curve for a supplier. It rewards having the chemistry and the capacity in place before anything happens, and it is contract-backed and durable rather than tied to the incidence of any one disease. It is also why the accelerating antiviral signal reads less like a wager on a particular pathogen and more like a standing bet on preparedness itself.
Who is actually on the hook
Trace this demand to the people who have to fill it, and a few distinct stakeholders come into focus. First are the antiviral active-ingredient makers and contract manufacturers — the firms that synthesize the molecules and, increasingly, hold the standing capacity preparedness contracts reward. For them, being paid to maintain a warm line is a different business from spot production, and a stickier one; the relationship is with a government that wants the option, not a market that wants the product this quarter.
Second are the preparedness buyers themselves — BARDA, HERA, and the national stockpile programs behind them. They are, in effect, purchasing readiness as a good, and their procurement choices shape which mechanisms and which suppliers get built out. Third, and easy to overlook, are the generics manufacturers who carry the treatment burden for hepatitis C and B once molecules come off patent or through access licensing. Those two infections are enormous global disease loads, and high-volume, low-cost generic supply — much of it flowing into lower- and middle-income markets — is a large, durable demand stream in its own right, running alongside the stockpile logic rather than competing with it.
The nuance the pattern hides
A signal this tidy invites over-reading, so a few cautions are worth keeping in view. Resistance is the first. Viruses mutate, and even conserved enzymes tolerate some change; a single drug used alone is an open invitation for escape. The hepatitis C win came from combinations for exactly that reason, and "broad-spectrum" should never be mistaken for "resistance-proof." The barrier is raised by hitting more than one machine at once, not by any single clever molecule.
The economics carry their own paradox. A stockpiled pandemic antiviral may sit unused until it expires — the value is optionality, the peace of mind of a shelf that is full when it is suddenly needed, and markets are notoriously bad at pricing insurance no one wants to cash in. Strip away the government pull mechanisms and the private return on this chemistry is thin, which is precisely why the policy scaffolding exists. And there is a road not taken: host-directed antivirals, which block the human factors a virus borrows rather than the virus's own enzymes. In principle these dodge resistance and cover many viruses at once, since the host does not mutate on the virus's schedule; in practice, perturbing human biology brings its own toxicity risk. It remains a live alternative, and a reminder that today's protease-and-polymerase consensus is a choice, not a law of nature.
Taken together, though, the observation is consistent: the world is quietly restocking its antiviral shelf, and it is doing so along two conserved enzymes it already knows how to attack. For a supplier, the signal that matters is not which virus makes headlines next. It is that the demand for this chemistry accumulates as readiness — a durable, policy-backed asset the world is building in the hope it never has to use in a hurry.
Editorial commentary from the Knitify Pharma Demand Radar. Not investment, legal, regulatory, or medical advice.